Aclarion, Inc. (ACON)
About Aclarion, Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $75.7K
- Net income
- -$7.2M
- Total assets
- $13.7M
- Market cap
- $6.0M
- Gross margin
- 9.0%
- Operating margin
- -9312.5%
- Net margin
- -9560.7%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $75.7K
- Cost of revenue
- $68.9K
- Gross profit
- $6.8K
- Operating expenses
- $7.1M
- Operating income
- -$7.1M
- Income tax
- $0
- Net income
- -$7.2M
- EPS (basic)
- $-13.61
- EPS (diluted)
- $-13.61
Balance sheet
- Total assets
- $13.7M
- Current assets
- $12.4M
- Total liabilities
- $837.3K
- Current liabilities
- $837.3K
- Shareholders’ equity
- $12.8M
Cash flow
- Operating cash flow
- -$7.2M
- Investing cash flow
- -$203.9K
- Financing cash flow
- $18.9M
- Net cash flow
- $11.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.0M
- EPS (diluted)
- $-13.61
- Shares outstanding
- 2.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 22, 2022
Aclarion, Inc. (ACON) Stock Price
- Reported a net loss of $7.2M in FY2025.
- Revenue grew 25% from FY2022 to FY2025.
- Gross margin of 9.0%, net margin -9560.7%.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aclarion, Inc..
Write a review
News about Aclarion, Inc.
News & sentiment via Polygon.io
Aclarion, Inc.: frequently asked questions
Is Aclarion, Inc. an American company?
Aclarion, Inc. is a US-based company headquartered in Broomfield, Colorado, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Aclarion, Inc. headquartered?
Aclarion, Inc. is headquartered in Broomfield, Colorado, United States.
Is Aclarion, Inc. publicly traded?
Yes — Aclarion, Inc. is a publicly traded company. Its stock trades under the ticker symbol ACON on the NASDAQ.
What does Aclarion, Inc. do?
Aclarion, Inc. is an American Medical Devices company in the Health & Beauty sector.
